Acta Neuropathologica
Acta Neuropathologica (commonly abbreviated Acta Neuropathol., CODEN ANLSBX) is a monthly peer-reviewed international journal in neuropathology published by Springer in Germany, carrying research on the pathology and pathogenesis of neurological disease, with manuscripts written in English.Acta Neuropathologica（常用缩写 Acta Neuropathol.，CODEN 为 ANLSBX）是由德国施普林格（Springer）出版的神经病理学领域国际同行评审月刊，刊载神经系统疾病的病理与发病机制研究，稿件以英文为主
Scope
The mission stated on the journal website is to publish the best articles on the pathology and pathogenesis of neurological disease, focusing on structural and molecular neuropathology using human tissue, animal models and in vitro systems.期刊官网公布的办刊宗旨是发表关于神经系统疾病病理学与发病机制的最优秀文章，聚焦以人组织、动物模型与体外系统为材料的结构神经病理学与分子神经病理学研究[1]
- Original papers: original research that produces a substantive advance in understanding a disease or pathological process, with emphasis on transparent methodology and verifiable conclusions. This is the journal's largest category by extent.原创论文： 刊载在认识某一疾病或病理过程上取得实质推进的原创研究，强调方法透明与结论可核验，是期刊最主要的篇幅来源
- Review articles: critical syntheses of a disease theme or a methodological problem, used to draw connections across scattered evidence.综述文章： 刊载就某一疾病主题或方法学问题所作的批判性梳理与综合评述，用于在分散证据之间建立联系
- Case reports: individual cases of teaching value or diagnostic interest, accompanied by a full pathological description and a literature review, used to flag unusual morphological combinations.病例报告： 刊载具有教学价值或诊断启发的个案研究，附以完整的病理描述与文献回顾，用于提示少见的形态学组合
- Scientific correspondence: concise short pieces used to report promptly experimental results, methodological improvements or academic opinions that warrant immediate release.科学通信： 刊载篇幅精炼的短篇，用于快速报告需要即时公开的实验结果、方法改良或学术观点
- Ethics requirements: manuscripts involving human studies must state that they were reviewed by the appropriate ethics committee and performed in accordance with an appropriate version of the Declaration of Helsinki, while animal experiments must declare compliance with the principles of laboratory animal care and applicable national legislation. The editors reserve the right to reject non-compliant manuscripts.伦理要求： 要求涉及人体研究的稿件说明已通过相应伦理委员会审查并符合赫尔辛基宣言的适当版本，动物实验稿件则须声明遵循实验动物护理原则及所在国的相关法规，编辑部保留拒稿权
It is worth noting that the journal does not treat morphological description and mechanistic investigation as an either-or choice. In a published editorial the Editor-in-Chief explains that the proportion of papers presenting both experimental data and human tissue data is rising, because cross-methodological corroboration is regarded as a necessary condition for major findings, and whether a paper carries clinical relevance is likewise weighed when acceptance is decided.需要指出的是，该刊并不把形态学描述与机制探讨视为二选一，主编在公开社论中说明同时呈现实验数据与人组织数据的稿件比例正在上升，因为跨方法学的相互印证被视为重大发现的必要条件，稿件是否具有临床相关性同样是录用时的重要考量
History
- 1961: founding. the journal was founded in 1961 by Franz Seitelberger, and Kurt A. Jellinger and later Werner Paulus succeeded as Editor-in-Chief. The title has not changed since.1961年：创刊。 该刊于 1961 年由 Franz Seitelberger 创办，此后由 Kurt A. Jellinger 与 Werner Paulus 相继担任执行主编，创刊至今刊名未变
- 1961 to present: the title. the journal has kept the name Acta Neuropathologica throughout and has never been formally renamed, although some databases record it in the form Acta Neuropathologica (Berlin), with the place of publication appended.创刊至今：刊名沿革。 该刊自创刊起一直沿用 Acta Neuropathologica 这一名称，从未正式更名，部分数据库中可见 Acta Neuropathologica（Berlin） 等带出版地的著录形式
- 2019: transfer of the editorship. Johannes Attems took over as Editor-in-Chief from Werner Paulus in January 2019, having co-edited the sister journal Acta Neuropathologica Communications with Paulus since 2014.2019年：主编交接。 Johannes Attems 于 2019 年 1 月接替 Werner Paulus 出任执行主编，在此之前他已自 2014 年起与 Paulus 共同主编姊妹刊 Acta Neuropathologica Communications
- Changing impact. the impact factor stood at about 2.6 when Paulus took over in 2003 and had reached 18.2 by 2018. It subsequently fell back and stabilised near 10, standing at 10.3 in 2025.影响力变化： 期刊影响因子在 Paulus 于 2003 年接手时约为 2.6，至 2018 年升至 18.2，此后回落并稳定在 10 附近，2025 年为 10.3
- Indexing and ranking. the journal is indexed in SCIE and is placed in the Q1 quartile in three Journal Citation Reports categories, namely clinical neurology, neurosciences and pathology. In the Chinese Academy of Sciences ranking it is a first-tier top journal in medicine, and the latest evaluation records no warning.收录与分区： 期刊被SCIE（科学引文索引扩展版）收录，在期刊引证报告中同时列于临床神经病学、神经科学与病理学三个学科的 Q1 区；在中国科学院期刊分区中为医学 1 区 Top 期刊，最新评估未见预警记录
Editors
The journal has an Editor-in-Chief, supported by associate editors, an editorial assistant and an international editorial board covering the subspecialties of neuropathology. Manuscripts are subject to peer review, with acceptance decided by the Editor-in-Chief.该刊设执行主编一人，另设执行编辑、编辑助理以及覆盖各神经病理学亚专业的国际编委会，稿件经同行评审后由执行主编决定录用
- Johannes Attems is the current Editor-in-Chief, a medical doctor whom the journal's public materials place at Newcastle University in the United Kingdom, working on the neuropathology of neurodegenerative diseases such as Alzheimer's disease.Johannes Attems：现任执行主编，医学博士，期刊公开资料显示其任职于纽卡斯尔大学（英国），研究方向为阿尔茨海默病等神经退行性疾病的神经病理学
- Werner Paulus is the former Editor-in-Chief, under whose tenure the impact factor was raised from 2.6 to 18.2, and he continued to advise the journal as a senior member of the editorial board after stepping down.Werner Paulus：前任执行主编，其任内曾将期刊影响因子由 2.6 提升至 18.2，卸任后仍以资深编委身份为期刊提供指导
- Editors of the sister journal. according to the Editor-in-Chief's editorial, the editorship of Acta Neuropathologica Communications was taken over by Jeroen Hoozemans and Jason Huse, and the editorial teams of the two journals work closely together.姊妹刊编辑： 按主编社论所述，Acta Neuropathologica Communications 的执行主编由 Jeroen Hoozemans 与 Jason Huse 承接，两刊编辑团队保持密切协作
- Full roster and submission information: the complete editorial board, the editorial policies, the ethics declarations and the submission contact details are given on the journal's official page.完整名单与投稿信息： 编委会全体成员、编辑政策、伦理声明与投稿联系方式见期刊官方页面[2]